

PATENT

Case Docket No. NIH175.001C1
Date: July 31, 2002

1645
JMS
8/19/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Usdin, et al.
Appl. No. : 10/014,162
Filed : December 11, 2001
For : PARATHYROID HORMONE
RECEPTOR LIGANDS
Examiner : Unknown
Group Art Unit : 1645

) I hereby certify that this correspondence and all marked
) attachments are being deposited with the United States
) Postal Service as first class mail in an envelope
) addressed to: United States Patent and Trademark
) Office, P.O. Box 2327, Arlington, VA 22202, on

July 31, 2002
(Date)

Nancy W. Vensko, Reg. No. 36,298

RECEIVED

AUG 09 2002

TECH CENTER 1600/2900

TRANSMITTAL LETTER

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202


ATTENTION: APPLICATION BRANCH

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with 16 references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

Nancy W. Vensko
Registration No. 36,298
Attorney of Record



NIH/75.001C1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Usdin, et al.) Group Art Unit: 1645
App. No. : 10/014,162)
Filed : December 11, 2001)
For : PARATHYROID HORMONE)
RECEPTOR LIGANDS)
Examiner : Unknown)

RECEIVED

AUG 09 2002

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

Enclosed is form PTO-1449 listing references that are also enclosed. This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 7/29/02

By: Nancy W. Vensko

Nancy W. Vensko
Registration No. 36,298
Attorney of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660
(805) 547-5585

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
NIH175.001C1APPLICATION NO.
10/014,162INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Usdin, et al.FILING DATE
December 11, 2001GROUP
1645

RECEIVED

AUG 09 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	1.	WO 02/33049	4/25/02	WO				
	2.	WO 98/04591	2/5/98	WO				

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

EXAMINER INITIAL		
	3.	Gardella, T. J., et al. (1996) Converting Parathyroid Hormone-related Peptide (PTHrP) into a Potent PTH-2 Receptor Agonist. J. Biol. Chem. 271(33):19888-19893.
	4.	Hoare, S. R. J., et al. (1999) Comparison of Rat and Human Parathyroid Hormone 2 (PTH2) Receptor Activation: PTH Is a Low Potency Partial Agonist at the Rat PTH2 Receptor. Endocrinology 140(10):4419-4425.
	5.	Hoare, S. R. J., et al. (2000) Tuberoinfundibular Peptide (7-39) [TIP(7-39)], a Novel, Selective, High-Affinity Antagonist for the Parathyroid Hormone-1 Receptor with No Detectable Agonist Activity. JPET 295(2):761-770
	6.	Hoare, S. R. J., et al. (2000) Molecular Determinants of Tuberoinfundibular Peptide of 39 Residues (TIP39) Selectively for the Parathyroid Hormone-2 (PTH2) Receptor. J. Biol. Chem. 275(35):27274-27283.
	7.	Mezey, E., et al. (1998) Anatomical Studies of the Rat PTH2 Receptor. Society for Neuroscience 24:244 (Abstract).
	8.	Nakata, T., et al. (1995) Role of Basic and Acidic Fragments in Delicious Peptides (Lys-Gly-Asp-Glu-Glu-Ser-Leu-Ala) and the Taste Behavior of Sodium and Potassium Salts in Acidic Oligopeptides. Biosci. Biotech. Biochem. 59(4):689-693.
	9.	Usdin, T. B., et al. (1995) Identification and Function Expression of a Receptor Selectively Recognizing Parathyroid Hormone, the PTH2 Receptor. J. Biol. Chem. 270(26):15455-15458.
	10.	Usdin, T. B., et al. (1996) Distribution of Parathyroid Hormone-2 Receptor Messenger Ribonucleic Acid in Rat. Endocrinology 137(10):4285-4297.
	11.	Usdin, T. B. (1997) The parathyroid hormone-2 receptor: current status. Exp. Mol. Med. 29(1):13-17.
	12.	Usdin, T. B. (1997) Evidence for a Parathyroid Hormone-2 receptor selective ligand in the hypothalamus. Endocrinology 138(2):831-834.
	13.	Usdin, T. B., et al. (1998) Progress on the Identification of a Novel PTH2 Receptor-Selective Peptide From the Hypothalamus. Society for Neuroscience 24:2044 (Abstract).
	14.	Usdin, T. B., et al. (1999) Distribution of the Parathyroid Hormone 2 Receptor in Rat: Immunolocalization Reveals Expression by Several Endocrine Cells. Endocrinology 140(7):3363-3371.
	15.	Usdin, T. B., et al. (1999) TIP39: a new neuropeptide and PTH2-receptor agonist from hypothalamus. Nature Neuroscience 2(11):941-943
	16.	Usdin, T. B. (2000) The PTH ₂ receptor and TIP39: a new peptide-receptor system. TIPS 21:128-130.

O:\DOCS\MXG\MXG-1477.DOC:vb 072602

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	